Merck to acquire Silence Therapeutics in $1.3bn RNA deal
Merck KGaA will acquire Silence Therapeutics for $1.3bn, adding divesiran, an investigational siRNA therapy for rare blood cancer, to its pipeline. The deal, approved by Silence's board, is expected to close in Q1 2027. Divesiran showed an 88% responder rate in Phase II trials, compared to 19% for placebo. The acquisition supports Merck's strategy in precision medicine and rare diseases.
How this was made
The 30-second read
Why it matters
The acquisition creates a larger RNA therapeutics platform, potentially accelerating Merck's entry into rare‑blood‑cancer treatments and enhancing its competitive position against other biotech firms.
Market read
First‑report M&A of over $1 bn in the RNA therapeutics space; likely to move Merck KGaA stock and affect sector sentiment.
What to watch
Financing via new debt could pressure Merck's balance sheet amid rising rates
Background
Merck KGaA, a German science and technology group, announced a $1.3 bn acquisition of UK biotech Silence Therapeutics to expand its RNA‑based rare‑disease portfolio.
Market effects
strengthens RNA therapeutics segment and rare‑disease pipeline
potential boost for European biotech M&A activity
adds to global RNA‑based drug development momentum
Counterpoint
Deal may be overpriced if Phase III fails; integration risk for Merck KGaA
Key entities
- companyMerck KGaA
German science and technology group acquiring Silence Therapeutics
- companySilence Therapeutics
UK biotech developing siRNA therapies, target of the acquisition
